RETA

RETA is an experimental research peptide modeled after GLP-1, GIP, and Glucagon receptor triagonist structures. It is available in lyophilized form for laboratory investigation and non-clinical research purposes only.

This product is not an approved drug, therapy, or supplement. It is offered exclusively for qualified professionals conducting biochemical, metabolic, or receptor-binding pathway research.

Key Features:

• Lyophilized peptide triagonist (GLP1-GIP-Glucagon model)
• Available in multiple strengths (10mg, 20mg, 30mg)
• Free of additives or preservatives
• Intended for preclinical and biochemical lab use
• Not for human or veterinary consumption

Scientific Context:

RETA mimics triagonist receptor sequences under investigation for potential metabolic, appetite, and signaling studies. While these classes (GLP-1, GIP, Glucagon) are FDA-recognized in approved drugs, this specific triagonist compound is investigational only and not approved for therapeutic use.

Composition:

• Active compound: GLP1-GIP-Glucagon peptide analog
• Form: Lyophilized powder
• Doses: 10mg / 20mg / 30mg
• Purity: ≥99% HPLC-verified
• Packaging: Sterile glass vial

How to Use:

• For research use only. Not for human or veterinary use.
• Reconstitute with bacteriostatic water using aseptic lab protocol
• Store at 2–8°C after reconstitution
• Do not freeze or expose to direct light

Quality & Testing:

• GMP-grade manufacturing
• Third-party tested for identity, purity, and sterility
• COA available upon request

Safety & Disclaimers:

This compound is not FDA-approved. It is not intended to diagnose, treat, or cure any condition.
For research use only. Not for injection or consumption in humans or animals.
This product must not be marketed, sold, or misrepresented as a supplement, drug, or therapeutic agent.